{"id":"NCT02112656","sponsor":"Imunon","briefTitle":"Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)","officialTitle":"A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2020-04-27","completion":"2020-04-27","firstPosted":"2014-04-14","resultsPosted":"2024-08-20","lastUpdate":"2024-08-20"},"enrollment":554,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma"],"interventions":[{"type":"DRUG","name":"ThermoDox","otherNames":["Lyso-Thermosensitive Liposomal Doxorubicin (LTLD)"]},{"type":"DRUG","name":"Dummy infusion","otherNames":["Placebo"]}],"arms":[{"label":"ThermoDox 50 mg/m2","type":"EXPERIMENTAL"},{"label":"Dummy infusion","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized radiofrequency ablation (sRFA).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"All subjects to be contacted every 3 months after radiological progression for vital status reporting. Subjects were followed for OS up to 68 months from randomization.","effectByArm":[{"arm":"ThermoDox 50 mg/m2","deltaMin":58.06,"sd":null},{"arm":"Dummy Infusion","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":61,"countries":["United States","Canada","China","Germany","Hong Kong","Italy","Malaysia","Philippines","Singapore","South Korea","Spain","Taiwan","Thailand","Vietnam"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":73,"n":274},"commonTop":["Alopecia","Neutropenia","Aspartate Aminotransferase Increased","Alanine Aminotransferase Increased","Pyrexia"]}}